RAHWAY - Merck , known as MSD outside of the United States and Canada, today announced results from the Phase 3 KEYNOTE-564 trial evaluating KEYTRUDA, Merck s anti-PD-1 therapy, for the adjuvant.
KEYNOTE-564 is the first Phase 3 trial to demonstrate superior overall survival with adjuvant therapy compared to placebo in patients with RCC
Late-breaking OS results selected for the official.